Profile of perampanel and its potential in the treatment of partial onset seizures

Neuropsychiatric Disease and Treatment

Volumn 9, Issue , 2013, Pages 629-637

  Rheims, Sylvain ^a,b   Ryvlin, Philippe ^a,b  

^a HOSPICES CIVILS DE LYON   (France)

^b LYON NEUROSCIENCE RESEARCH CENTER   (France)

Author keywords

Antiepileptic drug; Epilepsy; Partial seizures; Perampanel

Indexed keywords

ALPRAZOLAM; AMPA RECEPTOR; CARBAMAZEPINE; ETHINYLESTRADIOL; KAINIC ACID RECEPTOR; KETAMINE; KETOCONAZOLE; LEVONORGESTREL; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PERAMPANEL; PLACEBO; TALAMPANEL;

ADD ON THERAPY; AGGRESSIVENESS; ANXIETY; ASTHENIA; BODY WEIGHT; DIZZINESS; DRUG ANTAGONISM; DRUG BINDING SITE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FATALITY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; DRUG WITHDRAWAL; EUPHORIA; FALLING; FOCAL EPILEPSY; GAIT DISORDER; HEPATOBILIARY DISEASE; HUMAN; INSOMNIA; INTRACTABLE EPILEPSY; KIDNEY DYSFUNCTION; MONOTHERAPY; NEUROTOXICITY; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SOMNOLENCE; TREATMENT RESPONSE; VERTIGO; WEIGHT GAIN;

EID: 84877726358     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S30129     Document Type: Review

References (35)

1. Perucca E, Tomson T. The pharmacological treatment of epilepsy in adults. Lancet Neurol. 2011;10(5):446-456.
2. Kwan P, Brodie MJ. Early identifcation of refractory epilepsy. N Engl J Med. 2000;342(5):314-319.
3. Brodie MJ, Barry SJ, Bamagous GA, et al. Patterns of treatment response in newly diagnosed epilepsy. Neurol. 2012;78(20):1548-1554.
4. Perucca P, Gilliam FG. Adverse effects of antiepileptic drugs. Lancet Neurol. 2012;11(9):792-802.
5. Loscher W. Mechanisms of drug resistance. Epileptic Disord. 2005; 7(Suppl 1):S3-S9.
6. Pitkanen A, Lukasiuk K. Mechanisms of epileptogenesis and potential treatment targets. Lancet Neurol. 2011;10(2):173-186.
7. White HS, Smith MD, Wilcox KS. Mechanisms of action of antiepileptic drugs. Int Rev Neurobiol. 2007;81:85-110.
8. Stephen LJ, Brodie MJ. Antiepileptic drug monotherapy versus polytherapy: pursuing seizure freedom and tolerability in adults. Curr Opin Neurol. 2012;25(2):164-172.
9. Mayer ML, Armstrong N. Structure and function of glutamate receptor ion channels. Annu Rev Physiol. 2004;66:161-181.
10. Hwa GG, Avoli M. The involvement of excitatory amino acids in neocortical epileptogenesis: NMDA and non-NMDA receptors. Exp Brain Res. 1991;86(2):248-256.
11. Lee WL, Hablitz JJ. Involvement of non-NMDA receptors in picrotoxin-induced epileptiform activity in the hippocampus. Neurosci Lett. 1989; 107(1-3):129-134.
12. Perreault P, Avoli M. Physiology and pharmacology of epileptiform activity induced by 4-aminopyridine in rat hippocampal slices. J Neurophysiol. 1991;65(4):771-785.
13. Barna B, Szasz A, Vilagi I, et al. Anticonvulsive effect of AMPA receptor antagonist GYKI 52466 on 4-aminopyridine-induced cortical ictal activity in rat. Brain Res Bull. 2000;51(3):241-248.
14. Neuman R, Cherubini E, Ben-Ari Y. Epileptiform bursts elicited in CA3 hippocampal neurons by a variety of convulsants are not blocked by N-methyl-D-aspartate antagonists. Brain Res. 1988;459(2):265-274.
15. Hwa GG, Avoli M. Excitatory synaptic transmission mediated by NMDA and non-NMDA receptors in the superfcial/middle layers of the epileptogenic human neocortex maintained in vitro. Neurosci Lett. 1992;143(1-2):83-86.
16. Rogawski MA. Revisiting AMPA receptors as an antiepileptic drug target. Epilepsy Curr. 2011;11(2):56-63.
17. Chappell AS, Sander J W, Brodie MJ, et al. A crossover, add-on trial of talampanel in patients with refractory partial seizures. Neurol. 2002; 58(11):1680-1682.
18. Langan YM, Lucas R, Jewell H, et al. Talampanel, a new antiepileptic drug: single- and multiple-dose pharmacokinetics and initial 1-week experience in patients with chronic intractable epilepsy. Epilepsia. 2003;44(1):46-53.
19. Hanada T, Hashizume Y, Tokuhara N, et al. Perampanel: a novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy. Epilepsia. 2011;52(7): 1331-1340.
20. Ceolin L, Bortolotto ZA, Bannister N, et al. A novel anti-epileptic agent, perampanel, selectively inhibits AMPA receptor-mediated synaptic transmission in the hippocampus. Neurochem Int. 2012;61(4): 517-522.
21. Balannik V, Menniti FS, Paternain AV, et al. Molecular mechanism of AMPA receptor noncompetitive antagonism. Neuron. 2005;48(2): 279-288.
22. Templeton D, Ferry J. Pharmacokinetics of perampanel, a highly selective AMPA-type glutamate receptor antagonist. Epilepsia. 2009;50:98-99.
23. Fycompa [perampanel] [webpage on the Internet]. European Medicines Agency; 2012 [updated November 27, 2012]. Available from: http:// www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/med-icines/002434/human_med_001572.jsp&mid=WC0b01ac058001d124. Accessed March 1, 2013.
24. Marson AG, Williamson PR. Interpreting regulatory trials in epilepsy. Curr Opin Neurol. 2009;22(2):167-173.
25. Krauss GL, Bar M, Biton V, et al. Tolerability and safety of perampanel: two randomized dose-escalation studies. Acta Neurol Scand. 2012; 125(1):8-15.
26. French JA, Krauss GL, Steinhoff BJ, et al. Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305. Epilepsia. 2013;54(1): 117-125.
27. French JA, Krauss GL, Biton V, et al. Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304. Neurol. 2012;79(6):589-596.
28. Krauss GL, Serratosa JM, Villanueva V, et al. Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures. Neurol. 2012;78(18):1408-1415.
29. Krauss GL, Perucca E, Ben-Menachem E, et al. Perampanel, a selective, noncompetitive alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partial-onset seizures: interim results from phase III, extension study 307. Epilepsia. 2013;54(1):126-134.
30. Rektor I, Krauss GL, Bar M, et al. Perampanel Study 207: long-term open-label evaluation in patients with epilepsy. Acta Neurol Scand. 2012;126(4):263-269.
31. Rheims S, Perucca E, Cucherat M, et al. Factors determining response to antiepileptic drugs in randomized controlled trials. A systematic review and meta-analysis. Epilepsia. 2011;52(2):219-233.
32. Gazzola DM, Balcer LJ, French JA. Seizure-free outcome in randomized add-on trials of the new antiepileptic drugs. Epilepsia. 2007;48(7):1303-1307.
33. Rheims S, Cucherat M, Arzimanoglou A, et al. Greater response to placebo in children than in adults: a systematic review and meta-analysis in drug-resistant partial epilepsy. PLoS Med. 2008;5(8):e166.
34. Callaghan BC, Anand K, Hesdorffer D, et al. Likelihood of seizure remission in an adult population with refractory epilepsy. Ann Neurol. 2007;62(4):382-389.
35. Ryvlin P, Cucherat M, Rheims S. Risk of sudden unexpected death in epilepsy in patients given adjunctive antiepileptic treatment for refractory seizures: a meta-analysis of placebo-controlled randomised trials. Lancet Neurol. 2011;10(11):961-968.